Survivin -31G/C promoter polymorphism and P53 antibodies in breast cancer
Ahmad, N., zakhary, M., El- Noeman, S., Hemdan, S. (2019). Survivin -31G/C promoter polymorphism and P53 antibodies in breast cancer. EKB Journal Management System, 23(2), 62-67. doi: 10.21608/smj.2019.47254
Nagwa Sayed Ahmad; Madeha M. zakhary; Saad El-Din El- Noeman; Shimaa Hemdan. "Survivin -31G/C promoter polymorphism and P53 antibodies in breast cancer". EKB Journal Management System, 23, 2, 2019, 62-67. doi: 10.21608/smj.2019.47254
Ahmad, N., zakhary, M., El- Noeman, S., Hemdan, S. (2019). 'Survivin -31G/C promoter polymorphism and P53 antibodies in breast cancer', EKB Journal Management System, 23(2), pp. 62-67. doi: 10.21608/smj.2019.47254
Ahmad, N., zakhary, M., El- Noeman, S., Hemdan, S. Survivin -31G/C promoter polymorphism and P53 antibodies in breast cancer. EKB Journal Management System, 2019; 23(2): 62-67. doi: 10.21608/smj.2019.47254

Survivin -31G/C promoter polymorphism and P53 antibodies in breast cancer

Sohag Medical Journal
Article 17, Volume 23, Issue 2, April 2019, Page 62-67  XML PDF (107.38 K)
Document Type: Original Article
DOI: 10.21608/smj.2019.47254
View on SCiNiTO View on SCiNiTO
Authors
Nagwa Sayed Ahmad1; Madeha M. zakhary2; Saad El-Din El- Noeman3; Shimaa Hemdan4
1Debartment of Biochemistry, Faculty of Medicine, Sohag University.
2Department of Medical Biochemistry, Faculty of Medicine,Assiut University.
3Department of Medical Biochemistry, Faculty of Medicine, Tanta University.
4Department of Biochemistry, Faculty of Medicine, Sohag University.
Supplementary Files
References
  1. Altieri DC.,(2003): Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene ; 22 : 8581-9.
  2. Ambrosini G, Adida C and Altieri DC.,(1997): A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Mad ; 3 : 917-21.
  3. Angelopoulou, K., Diamandis, E. P., Sutherland, D. J. A., Kellen, J. A., and Bunting, P. S.,(1994):  Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int. J. Cancer, 58: 480–487.
  4. Be´roud, C., and Soussi, T.(1998):  p53 gene mutation: software and database. Nucleic Acids Res., 26: 200–204.
  5. Caron de Fromentel, C., May-Levin, F., Mouriesse, H., Lemerle, J., Chandrasekaran, K., and May, P. (1987):  Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B-cell lymphoma. Int. J. Cancer, 39: 185–189.
  6. Fukuda S and Pelus LM.,(2001): Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34(+) cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis. Blood; 98:2091 – 100.
  7. Hoffmann, L.S., Etzrodt, J., Willkomm, L., Sanyal, A., Scheja, L., Fischer, A.W.C., Stasch, J.-P., Bloch, W., Friebe, A., Heeren, J., and Pfeifer, A. (2015). Stimulation of soluble guanylyl cyclase protects against obesity by recruiting brown adipose tissue. Nat. Commun. 6, 7235.
  8. Khan Z and Bisen PS.,(2013): Oncoapoptotic signaling and deregulated target genes in cancers: special reference to oral cancer. Biochim Biophys Acta 2013; 1836 : 123-45. 48.
  9. Lubin, R., Schlichtholz, B., Teillaud, J. L., Garay, E., Bussel, A., Wild, C., and Soussi, T. (1995):  p53 antibodies in patients with various types of cancer: assay, identification, and characterization. Clin. Cancer Res., 1: 1463–1469.
  10. Reed JC.(2003): Apoptosis-targeted therapies for cancer. Cancer Cell 2003; 3: 17-22.
  11. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: a cancer journal for clinicians. Jan 2013;63(1):11-30.
  12. Monticciolo DL, Newell MS, Moy L, Niell B, Monsees B, Sickles EA.J Am Coll Radiol.,(2018): Breast Cancer Screening in Women at Higher-Than-Average Risk: Recommendations From the ACR. Mar;15(3 Pt A):408-414. DOI: 10.1016/j.jacr.2017.11.034.
  13. Mao, L., Lee, J. S., Kurie, J. M., Fan, Y. H., Lippman, S. M., Lee, J. J., Ro, J. Y., Broxson, A., Yu, R., Morice, R. C., Kemp, B. L., Khuri, F. R., Walsh, G. L., Hittelman, W. N., and Hong, W. K. (1997): Clonal genetic alterations in the lungs of current and former smokers. J. Natl. Cancer Inst., 89: 857–862.
  14. Yonish-Rouach, E., Resnitzky, D., Lotem, J., Sachs, L., Kimchi, A., and Oren, M. (1991): Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature (Lond.), 352: 345–347.

 

 

 

Statistics
Article View: 170
PDF Download: 243